Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Raderer

Showing results (161-170 of 172) with videos related to

Pageof 18
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Current Pharmaceutical Design|August 13, 2002
Experience with indium-111 and yttrium-90-labeled somatostatin analogsI Virgolini, T Traub, C Novotny, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Cancer Research|March 14, 2001
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphomaN Welzel, T Le, R Marculescu, et al.
Endocrine-Related Cancer|June 24, 2024
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET studyE Baudin, J Capdevila, D Hörsch, et al.
Leukemia|September 10, 2004
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sitesB Streubel, I Simonitsch-Klupp, L Müllauer, et al.
Leukemia|June 4, 2010
Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanismR A Hamoudi, A Appert, H Ye, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapyI Virgolini, T Traub, M Leimer, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
Pageof 18

Showing results (161-170 of 172) with videos related to

Sort By:
Pageof 18
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 26, 1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patientsI Virgolini, I Szilvasi, A Kurtaran, et al.
Current Pharmaceutical Design|August 13, 2002
Experience with indium-111 and yttrium-90-labeled somatostatin analogsI Virgolini, T Traub, C Novotny, et al.
European Journal of Nuclear Medicine|October 1, 1996
In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCTI Virgolini, P Angelberger, S Li, et al.
Nuclear Medicine and Biology|August 1, 1996
123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tractI Virgolini, M Raderer, A Kurtaran, et al.
Cancer Research|March 14, 2001
Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphomaN Welzel, T Le, R Marculescu, et al.
Endocrine-Related Cancer|June 24, 2024
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET studyE Baudin, J Capdevila, D Hörsch, et al.
Leukemia|September 10, 2004
Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sitesB Streubel, I Simonitsch-Klupp, L Müllauer, et al.
Leukemia|June 4, 2010
Differential expression of NF-kappaB target genes in MALT lymphoma with and without chromosome translocation: insights into molecular mechanismR A Hamoudi, A Appert, H Ye, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|August 10, 2000
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapyI Virgolini, T Traub, M Leimer, et al.
Leukemia|December 3, 2016
Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinibL Kazianka, C Drucker, C Skrabs, et al.
Pageof 18